Cubist Pharmaceuticals, Inc. Enrolls 1st Patient in Phase 3 CB-5945 Program for the Treatment of Opioid-Induced Constipation

Published: Oct 31, 2012

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the initiation of the Phase 3 CB-5945 opioid-induced constipation (OIC) Ascent program with the enrollment of the first patient in the long-term safety study, which is one of four registrational studies in patients with chronic non-cancer pain.

Back to news